Ambrx Biopharma Inc.
Ambrx Biopharma Inc.（AMAM）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · AMAM · 截至 2023年12月31日
股东结构概览
76
机构持有人数
▲ 16 vs Q3
$912.65M
机构持仓总市值
▲ $344.36M vs Q3
63.29M
总流通股
freeFloat 34.64%
64.09M
13F 申报持股数
▲ 14.67M vs Q3
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
AMAM 最大股东 · 机构持仓
Q4 2023 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
DARWIN GLOBAL MANAGEMENT, LTD. biological products, (no diagnostic substances) | 16.69M | 26.81% | 26.81% | $237.65B | Feb 14, 2024 | NEW |
CORMORANT ASSET MANAGEMENT, LP biological products, (no diagnostic substances) | 11.23M | 18.04% | 18.04% | $159.93B | Feb 14, 2024 | NEW |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 4.35M | 6.99% | 6.99% | $61.98B | Feb 14, 2024 | NEW |
D. E. SHAW & CO., INC. biological products, (no diagnostic substances) | 4.24M | 6.81% | 6.81% | $60.38B | Feb 14, 2024 | NEW |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 3.71M | 5.96% | 5.96% | $52.84B | Feb 14, 2024 | NEW |
NEXTECH INVEST LTD. biological products, (no diagnostic substances) | 3.13M | 5.03% | 5.03% | $44.56B | Feb 14, 2024 | NEW |
BALYASNY ASSET MANAGEMENT L.P. biological products, (no diagnostic substances) | 2.15M | 3.46% | 3.46% | $30.68B | Feb 14, 2024 | NEW |
LOGOS GLOBAL MANAGEMENT LP biological products, (no diagnostic substances) | 2.10M | 3.37% | 3.37% | $29.90B | Feb 14, 2024 | NEW |
VR ADVISER, LLC biological products, (no diagnostic substances) | 2.07M | 3.33% | 3.33% | $29.48B | Feb 14, 2024 | NEW |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 2.04M | 3.28% | 3.28% | $29.08B | Feb 14, 2024 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q4 2023 对比上季度
Q4 2023
0
增持
+0 股50
新建仓
首次建仓0
减持
−0 股0
清仓
完全退出净股数变化（前50家）
+0
+0 / −0
净新增持仓人
+50
新建 50 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
AMAM 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
7
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
O'Connor Daniel J. President and CEO | Dec 11, 2023 | Award | 750,000 | — | — | 1.36M | Form 4 ↗ |
O'Connor Daniel J. President and CEO | Oct 27, 2023 | Sale | 50,012 | $9.82 | $491.1K | 342.8K | Form 4 ↗ |
Cormorant Asset Management, LP 10 percent owner | Oct 23, 2023 | Purchase | 1,307,311 | $6.99 | $9.14M | 11.23M | Form 4 ↗ |
Cormorant Asset Management, LP 10 percent owner | Sep 18, 2023 | Purchase | 751,233 | $9.24 | $6.94M | 69.47M | Form 4 ↗ |
Cormorant Asset Management, LP 10 percent owner | Sep 15, 2023 | Purchase | 1,401,505 | $9.05 | $12.68M | 68.71M | Form 4 ↗ |
DALESANDRO MARGARET director | Sep 1, 2023 | Award | 125,000 | — | — | 125.0K | Form 4 ↗ |
DALESANDRO MARGARET director | Sep 1, 2023 | Award | 70,833 | — | — | 70.8K | Form 4 ↗ |
O'Connor Daniel J. President and CEO | Jul 5, 2023 | Award | 1,216,500 | $2.38 | $2.90M | 1.22M | Form 4 ↗ |
Nelson Sonja Chief Financial Officer | Jul 5, 2023 | Award | 389,000 | $2.38 | $925.8K | 389.0K | Form 4 ↗ |
Aromando Andrew Chief Operating Officer | Jul 5, 2023 | Award | 389,000 | $2.38 | $925.8K | 389.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Ambrx Biopharma Inc.（AMAM）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 65.36%，散户及公众持股约占剩余的 0.00%。
Ambrx Biopharma Inc. 最大机构股东为 DARWIN GLOBAL MANAGEMENT, LTD.，截至 December 31, 2023 持有约 16.69 million 股，占总流通股的 26.81%。
目前共有 76 家机构持有 AMAM 股票，合计持仓市值约 $912,651,263，数据来源为最新 SEC 13F 申报。
常见问题
AMAM ownershipAmbrx Biopharma Inc.（AMAM）主要由机构投资者持有，机构持股约 100.0%。最大股东为 DARWIN GLOBAL MANAGEMENT, LTD.，持股比例 26.81%。内部人员持股约 65.36%。数据来源 SEC Form 13F，截至 December 31, 2023。